I think you have missed the point.. Their focus is not on sales in the sas market, but on products for drug approvals where income can be much higher. And by the looks of the cost of sales in quarterly reports vs income for most cannabis companies so far, i'd say its a good decision..
- Forums
- ASX - By Stock
- Ann: Quarterly Cashflow and Market Update September 2021
I think you have missed the point.. Their focus is not on sales...
-
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
AVH
Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin
TG1
TechGen Metals kicks off airborne geophys survey at Sally Downs copper play – a first for the permit
GML
Gateway Mining sells WA Eastern Montague gold project to Brightstar for $14M – half of that in shares
Add AC8 (ASX) to my watchlist
|
|||||
Last
4.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.62M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
MND
Albemarle lithium downsize burns $200M hole in Monadelphous's pocket as latter's contracts terminated
TG1
TechGen Metals kicks off airborne geophys survey at Sally Downs copper play – a first for the permit
AC8 (ASX) Chart |
Day chart unavailable